An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson, +40

Science

Viral DiagnosticsWorldwide OutbreakImmunologyImmunotherapeuticsCovid-19 Epidemiology +14

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras, Rhys Jones, Brandon J. Anson, +49

Nature Communications

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller, +45

Cancer Cell

Tumor BiologyOncologyCdk2/4/6 InhibitorMedicineTumor Cell Cycle +8

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Britton Boras, Rhys Jones, Brandon J. Anson, +46

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer

Kevin D. Freeman‐Cook, Robert L. Hoffman, Douglas C. Behenna, +30

Journal of Medicinal Chemistry

Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans

Heather Eng, Alyssa Dantonio, Eugene P. Kadar, +10

Drug Metabolism and Disposition

Nanoparticles for Improved Local Retention after Intra-Articular Injection into the Knee Joint

Michael M. Morgen, David Tung, Britton Boras, +3

Pharmaceutical Research

A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner, +44

Journal of Medicinal Chemistry

A Computational Modeling and Simulation Approach to Investigate Mechanisms of Subcellular cAMP Compartmentation

Pei‐Chi Yang, Britton Boras, Mao-Tsuen Jeng, +5

PLoS Computational Biology

Cardiac MuscleBiophysical ModelingEngineeringCytoskeletonCell Biophysics +22

Discovery of SARS-CoV-2 papain-like protease (PL ^pro ) inhibitors with efficacy in a murine infection model

Michelle R. Garnsey, Matthew C. Robinson, Luong T. Nguyen, +37

Science Advances